

**Listing of Claims**

This listing of claims will replace all prior versions and listing of claims in the application:

1. (Original) A method for reducing tumor burden comprising administering a therapeutically effective amount of an EGFR inhibitor to a human patient suffering from a cancer in which the cancer cells express the CCK<sub>8</sub>/gastrin receptor and express little or no EGFR.
2. (Original) The method of claim 1, wherein the EGFR inhibitor is a small molecule.
3. (Withdrawn) A method for inhibiting recurrence of gross cystic disease of the breast and/or inhibiting the progression from gross cystic disease of the breast to breast cancer comprising administering to a patient who presently has or has had gross cystic disease of the breast a therapeutically effective amount of an EGFR inhibitor.
4. (Withdrawn) The method of claim 3, wherein the EGFR inhibitor is administered orally.
5. (Withdrawn) A method for preventing or reducing the frequency or severity of transient ischemic attacks or strokes comprising administering to a patient suffering from cerebral ischemia a therapeutically effective amount of an EGFR inhibitor.
6. (Withdrawn) The method of claim 5, wherein the patient suffers from hypertension.
7. (Withdrawn) The method of claim 5, wherein the patient suffers from atherosclerosis.
8. (Previously Presented) The method of claim 1, wherein the EGFR inhibitor is a protein.
9. (Previously Presented) The method of claim 1, further comprising administering an inhibitor of the interaction between gastrin and the CCK<sub>8</sub>/gastrin receptor.
10. (Previously Presented) The method of claim 9, wherein the inhibitor of the interaction between gastrin and the CCK<sub>8</sub>/gastrin receptor is a protein.
11. (Previously Presented) The method of claim 9, wherein the inhibitor of the interaction between gastrin and the CCK<sub>8</sub>/gastrin receptor is a small molecule.
12. (Previously Presented) The method of claim 2, further comprising administering an inhibitor of the interaction between gastrin and the CCK<sub>8</sub>/gastrin receptor.
13. (Previously Presented) The method of claim 12, wherein the inhibitor of the interaction between gastrin and the CCK<sub>8</sub>/gastrin receptor is a protein.
14. (Previously Presented) The method of claim 12, wherein the inhibitor of the interaction between gastrin and the CCK<sub>8</sub>/gastrin receptor is a small molecule.
15. (Previously Presented) The method of claim 8, further comprising administering an inhibitor of the interaction between gastrin and the CCK<sub>8</sub>/gastrin receptor.

16. (Previously Presented) The method of claim 15, wherein the inhibitor of the interaction between gastrin and the CCK<sub>B</sub>/gastrin receptor is a protein.

17. (Previously Presented) The method of claim 15, wherein the inhibitor of the interaction between gastrin and the CCK<sub>B</sub>/gastrin receptor is a small molecule.